...
首页> 外文期刊>Oncogene >Expression of the chrXq27.3 miRNA cluster in recurrent ovarian clear cell carcinoma and its impact on cisplatin resistance
【24h】

Expression of the chrXq27.3 miRNA cluster in recurrent ovarian clear cell carcinoma and its impact on cisplatin resistance

机译:chrXq27.3 miRNA簇在复发性卵巢透明细胞癌中的表达及其对顺铂耐药的影响

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Ovarian clear cell carcinoma (OCCC) is a histological subtype of epithelial ovarian cancer and exhibits dismal prognosis due to chemoresistance. Moreover, only few effective therapeutic options exist for patients with recurrent OCCC, and an understanding of its molecular characteristics is essential for the development of novel therapeutic approaches. In the present study, we investigated unique MicroRNAs (miRNA) profiles in recurrent/metastatic OCCC and the role of miRNAs in cisplatin resistance. Comprehensive miRNA sequencing revealed that expression of several miRNAs, including miR-508-3p, miR-509-3p, miR-509-3-5p, and miR-514a-3p was remarkably less in recurrent cancer tissues when compared with that in paired primary cancer tissues. These miRNAs are located in the chrXq27.3 region on the genome. Moreover, its expression was negative in omental metastases in two patients with advanced OCCC. In vitro analyses revealed that overexpression of miR-509-3p and miR-509-3-5p reversed cisplatin resistance and yes-associated protein 1 (YAP1) was partially responsible for the resistance. Immunohistochemistry revealed that YAP1 expression was inversely correlated with the chrXq27.3 miRNA cluster expression. In conclusion, these findings suggest that alteration of the chrXq27.3 miRNA cluster could play a critical role in chemoresistance and miRNAs in the cluster and their target genes can be potential therapeutic targets.
机译:卵巢透明细胞癌 (OCCC) 是上皮性卵巢癌的一种组织学亚型,由于化疗耐药而预后惨淡。此外,对于复发性OCCC患者,只有少数有效的治疗选择,了解其分子特征对于开发新的治疗方法至关重要。在本研究中,我们研究了复发性/转移性OCCC中独特的MicroRNA(miRNA)谱以及miRNA在顺铂耐药中的作用。综合miRNA测序结果显示,与配对的原发性癌组织相比,miR-508-3p、miR-509-3p、miR-509-3-5p和miR-514a-3p等几种miRNA在复发性癌组织中的表达明显较低。这些 miRNA 位于基因组的 chrXq27.3 区域。此外,在两名晚期OCCC患者的网膜转移中,其表达呈阴性。体外分析显示,miR-509-3p 和 miR-509-3-5p 的过表达逆转了顺铂耐药性,yes 相关蛋白 1 (YAP1) 是耐药性的部分原因。免疫组化结果显示,YAP1表达与chrXq27.3 miRNA簇表达呈负相关。综上所述,这些发现表明chrXq27.3 miRNA簇的改变可能在化疗耐药中起关键作用,并且该簇中的miRNA及其靶基因可以成为潜在的治疗靶点。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号